Norma B Coe1, Lindsay White2, Melissa Oney1, Anirban Basu3, Eric B Larson4. 1. Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 2. Center for Health Care Quality and Outcomes, RTI International, Seattle, Washington, USA. 3. Department of Pharmacy, University of Washington, Seattle, Washington, USA. 4. Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
Abstract
INTRODUCTION: We estimate the spending attributable to Alzheimer's disease and related dementias (ADRD) to the United States government for the first 5 years post-diagnosis. METHODS: Using data from the Health and Retirement Study matched to Medicare and Medicaid claims, we identify a retrospective cohort of adults with a claims-based ADRD diagnosis along with matched controls. RESULTS: The costs attributable to ADRD are $15,632 for traditional Medicare and $8833 for Medicaid per dementia case over the first 5 years after diagnosis. Seventy percent of Medicare costs occur in the first 2 years; Medicaid costs are concentrated among the longer-lived beneficiaries who are more likely to need long-term care and become Medicaid eligible. DISCUSSION: Because the distribution of the incremental costs varies over time and between insurance programs, when interventions occur and the effect on the disease course will have implications for how much and which program reaps the benefits.
INTRODUCTION: We estimate the spending attributable to Alzheimer's disease and related dementias (ADRD) to the United States government for the first 5 years post-diagnosis. METHODS: Using data from the Health and Retirement Study matched to Medicare and Medicaid claims, we identify a retrospective cohort of adults with a claims-based ADRD diagnosis along with matched controls. RESULTS: The costs attributable to ADRD are $15,632 for traditional Medicare and $8833 for Medicaid per dementia case over the first 5 years after diagnosis. Seventy percent of Medicare costs occur in the first 2 years; Medicaid costs are concentrated among the longer-lived beneficiaries who are more likely to need long-term care and become Medicaid eligible. DISCUSSION: Because the distribution of the incremental costs varies over time and between insurance programs, when interventions occur and the effect on the disease course will have implications for how much and which program reaps the benefits.
Authors: Murtuza F Bharmal; Seema Dedhiya; Bruce A Craig; Michael Weiner; Marc Rosenman; Laura P Sands; Ankita Modi; Caroline Doebbeling; Joseph Thomas Journal: Am J Geriatr Psychiatry Date: 2012-01 Impact factor: 4.105
Authors: Lindsay White; Paul Fishman; Anirban Basu; Paul K Crane; Eric B Larson; Norma B Coe Journal: Health Serv Res Date: 2019-03-13 Impact factor: 3.402
Authors: Michael D Hurd; Paco Martorell; Adeline Delavande; Kathleen J Mullen; Kenneth M Langa Journal: N Engl J Med Date: 2013-04-04 Impact factor: 91.245